Target intelligence / Profile preview

β-Lactamase (Class A, C, and D)

Molecular classification
Enzyme, Hydrolase, Antibiotic resistance enzyme
01

Overview

β-Lactamases are enzymes produced by bacteria to inactivate β-lactam antibiotics by hydrolyzing the β-lactam ring, thus conferring resistance. The Ambler molecular classification groups them into four classes (A, B, C, D); Class A, C, and D β-lactamases are serine hydrolases that use a serine residue at the active site to hydrolyze their substrates, while class B comprises metallo-β-lactamases requiring zinc, and is not included here. Class A includes enzymes such as TEM, SHV, CTX-M, KPC; class C includes AmpC-type enzymes; and class D includes OXA-type enzymes, with each class associated with varying substrate profiles and resistance patterns. These enzymes play a major role in clinical antibiotic resistance, particularly to penicillins, cephalosporins, and carbapenems, posing a significant threat to the efficacy of current antibiotic therapies.

Other names
Beta-lactamase class ABeta-lactamase class CBeta-lactamase class DSerine beta-lactamaseClass A beta-lactamaseClass C beta-lactamaseClass D beta-lactamaseESBL enzymes (for some class A and D variants)AmpC beta-lactamase (for class C)OXA-type beta-lactamase (for class D)
02

Mechanism of action

Catalytic hydrolysis of the beta-lactam ring in antibiotics, rendering the drugs inactive. This involves covalent acyl-enzyme intermediate formation via serine hydrolysis at the active site. Resistance is thereby provided against broad-spectrum beta-lactams through this enzymatic inactivation.

03

Biological functions

Hydrolysis of beta-lactam antibioticsAntibiotic resistanceBacterial drug inactivation
04

Disease associations

InfectionAntibiotic resistance in bacterial infections
05

Safety considerations

Rapid emergence and spread of resistance, especially in nosocomial infectionsLimited therapeutic options for infections caused by bacteria producing multiple beta-lactamase classesDetection challenges due to diverse variants and overlapping substrate profilesIneffectiveness of many beta-lactamase inhibitors for certain classes (e.g., OXA, AmpC)
06

Interacting drugs

Beta-lactam antibiotics (e.g., penicillins, cephalosporins, carbapenems, monobactams)

5 more in the full profile.

07

Biomarkers

Presence of specific beta-lactamase genes (e.g., blaTEM, blaSHV, blaCTX-M, blaKPC, blaOXA, blaAmpC) detected by PCR or molecular assaysPhenotypic resistance to extended-spectrum cephalosporins or carbapenems

Beyond the preview

Go deeper on β-Lactamase (Class A, C, and D).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on β-Lactamase (Class A, C, and D).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call